Trade Elicit Therapeutics Inc. - ELTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2910 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.3295 |
| Open | 6.1895 |
| 1-Year Change | 20.53% |
| Day's Range | 6.1895 - 6.4295 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 6.2195 | 0.0300 | 0.48% | 6.1895 | 6.4295 | 6.1395 |
| Jan 16, 2025 | 6.3295 | -0.0700 | -1.09% | 6.3995 | 6.4895 | 6.1895 |
| Jan 15, 2025 | 6.2395 | 0.0500 | 0.81% | 6.1895 | 6.3795 | 6.1895 |
| Jan 14, 2025 | 6.0495 | 0.1100 | 1.85% | 5.9395 | 6.2795 | 5.9395 |
| Jan 13, 2025 | 5.8395 | -0.2000 | -3.31% | 6.0395 | 6.0395 | 5.7695 |
| Jan 10, 2025 | 6.1195 | 0.6200 | 11.27% | 5.4995 | 6.1195 | 5.4595 |
| Jan 8, 2025 | 5.4995 | -0.3500 | -5.98% | 5.8495 | 6.2995 | 5.2795 |
| Jan 7, 2025 | 5.8995 | 0.4100 | 7.47% | 5.4895 | 6.0195 | 5.3895 |
| Jan 6, 2025 | 5.7095 | 0.4600 | 8.76% | 5.2495 | 5.8595 | 5.2395 |
| Jan 3, 2025 | 5.5295 | 0.5600 | 11.27% | 4.9695 | 5.5495 | 4.9695 |
| Jan 2, 2025 | 5.1095 | 0.1800 | 3.65% | 4.9295 | 5.1095 | 4.8895 |
| Dec 31, 2024 | 4.8795 | 0.1100 | 2.31% | 4.7695 | 4.9795 | 4.6895 |
| Dec 30, 2024 | 4.9095 | -0.2400 | -4.66% | 5.1495 | 5.1495 | 4.8895 |
| Dec 27, 2024 | 5.0795 | -0.0200 | -0.39% | 5.0995 | 5.0995 | 4.9895 |
| Dec 26, 2024 | 5.0595 | -0.0800 | -1.56% | 5.1395 | 5.2195 | 4.9895 |
| Dec 24, 2024 | 5.2195 | 0.2300 | 4.61% | 4.9895 | 5.2195 | 4.9895 |
| Dec 23, 2024 | 4.9895 | 0.0500 | 1.01% | 4.9395 | 4.9995 | 4.9395 |
| Dec 20, 2024 | 4.6895 | -0.2500 | -5.06% | 4.9395 | 4.9895 | 4.3895 |
| Dec 19, 2024 | 4.9995 | 0.0500 | 1.01% | 4.9495 | 4.9995 | 4.8195 |
| Dec 18, 2024 | 4.9995 | 0.0500 | 1.01% | 4.9495 | 5.1095 | 4.9495 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com